Cytokine Indexes in Pemphigus Vulgaris: Perception of Its Immunpathogenesis and Hopes for Non-Steroidal Treatment

Authors

  • Ali Asilian Department of Dermatology, Isfahan University of Medical Science, Isfahan, Iran.
  • Ali Saffaei Pharmacy Students’ Research Committee, School of Pharmacy, Isfahan University of Medical sciences, Isfahan, Iran.
  • Bahareh Abtahi-Naeini Skin Diseases and Leishmaniasis Research Center, Department of Dermatology, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Mohsen Masjedi Department of Immunology, Isfahan University of Medical Science, Isfahan, Iran.
  • Mohsen Pourazizi Cancer Research Center, Semnan University of Medical Sciences, Semnan, Iran.
  • Nafiseh Esmaeil Department of Immunology, Isfahan University of Medical Science, Isfahan, Iran.
Abstract:

Pemphigus vulgaris (PV) is a chronic autoimmune blistering disease of the skin, in whichloss of adhesion between keratinocytes is caused by autoantibodies. It has been hypothesizedthat cytokines play an essential role in the pathogenesis of PV. This study aimed to investigatethe other immunopathological aspects of PV by determining the serum levels of cytokines inPV patients to find another treatment strategy except corticosteroid therapy.Twenty-three patients with PV and a control group consisting of 24 healthy subjects werestudied. Interleukin (IL)-2, IL-4, IL-6, IL10, IL-12, IL-17 and interferon-gamma (IFN-γ) weremeasured in the sera of patients by the enzyme-linked immunosorbent assay (ELISA) method.The serum levels of IL-2, IL-4, IL-17 and IFN-γ in most patients and controls wereundetectable. The serum concentrations of IL-10 in the patients and controls were undetectable,nevertheless, the mean serum levels of this cytokine was 64.375 pg/mL in four patients. Themean serum levels of pro-inflammatory cytokine IL-6 increased significantly in the patients,compared to the controls (169.50 vs. 75.62 pg/mL) (P < 0.05). The same was observed foranother pro-inflammatory cytokine, IL-12 (135.33 vs. 86.28 pg/mL) (P < 0.05).Based on the results of this study it can be concluded that the Type 2 T helper cytokine(IL-6) and macrophage-derived cytokine (IL-12) have essential roles in PV pathophysiology.In addition, the potential clinical application of Th1/Th2 type cytokine-based therapy in PVshould be considered in next studies.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Homeopathy treatment and pemphigus vulgaris: case series

Homeopathy treatment and pemphigus vulgaris: case series Dr. Shirani, A.M.* - Dr. Mousavi, F.** *Assistant Professor of Oral Medicine & Diagnosis Dept., Faculty of Dentistry, Isfahan University of Medical Sciences. **Associate Professor of Oral Medicine & Diagnosis Dept., Faculty of Dentistry, Tehran University / Medical Sciences. Abstract Introduction: Pemphigus vulgaris is a chronic vesicular...

full text

Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil.

BACKGROUND Mycophenolate mofetil is increasingly being used as a corticosteroid-sparing agent in immunosuppressive regimens. OBJECTIVE To elucidate the effectiveness of mycophenolate as adjuvant therapy in the treatment of both pemphigus vulgaris and pemphigus foliaceus. DESIGN Historical prospective study. SETTING University hospital. PATIENTS The study included 42 consecutive patients...

full text

Pemphigus vulgaris: approach to treatment.

The therapeutic management of pemphigus vulgaris (PV) is centered around immunosuppression, which can be generalized, as in the use of corticosteroids or steroid sparing agents, or specific, as in therapeutic blockage of autoantibody production, certain cytokines, or signaling pathways. Currently, the backbone of treatment for PV, particularly, first line therapy, remains systemic corticosteroi...

full text

Rituximab in the Treatment of Pemphigus Vulgaris

INTRODUCTION Rituximab is increasingly used in patients with pemphigus vulgaris (PV) who are nonresponders to conventional therapy. METHODS A PubMed search was conducted using the words pemphigus vulgaris and rituximab therapy from papers published between 2000 and 2012. Two protocols were used. In the lymphoma protocol, patients received four weekly infusions of rituximab (dose 375 mg/m(2))....

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 16  issue 3

pages  1223- 1229

publication date 2017-07-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023